Inclusion Criteria:

- Patients were eligible if they had histologic or cytologic verification of small cell
lung cancer (SCLC) and were radiographically confirmed limited-stage

- Patients with contralateral mediastinal and ipsilateral supraclavicular
lymphadenopathy were also included.

- The patients should be between 18 and 75 years old without previous thoracic
radiotherapy, chemotherapy or biotherapy.

- Karnofsky performance status was ≥ 80.

- Forced expiratory volume at 1 second (FEV1) ≥ 1 L.

- Had measurable or assessable disease.

- Neutrophilic granulocyte ≥ 1.5×109/L, haemoglobin ≥ 100 g/L, platelet count ≥
100×109/L.

- Serum creatine and bilirubin < 1.5 × the upper normal limit (UNL), aminotransferase <
2 × UNL.

- Weight loss was less than 10% within 6 months before diagnosis.

- Written informed consent was required from all patients.

Exclusion Criteria:

- Patients were ineligible if they had a history of other malignant diseases except for
non-melanomatous skin cancer and carcinoma in situ of the cervix, or any
contraindications for chemoradiotherapy, malignant pleural and/or pericardial
effusion.